Search

Displaying results 3411 - 3420 of 5419 in total
  1. Drug

    Cefcapene

    go.drugbank.com/drugs/DB13461
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Hexoprenaline

    go.drugbank.com/drugs/DB08957
    ApprovedWithdrawn

    Hexoprenaline is a stimulant of beta 2 adrenergic receptors. It is used as a bronchodilator, antiasthmatic, and tocolytic agent.

    Categories: Adrenergics for Systemic Use
  3. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic ...

  4. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  5. Drug

    ARQ 171

    go.drugbank.com/drugs/DB06034
    Investigational

  6. Drug

    Mizolastine

    go.drugbank.com/drugs/DB12523
    Approved

    Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

    Categories: Antihistamines for Systemic Use
  7. Drug

    Isoetharine

    go.drugbank.com/drugs/DB00221
    Approved

    Isoetharine is a relatively selective beta-2 adrenergic agonist. It is a catechol-like agent. Isoetharine is a fast-acting bronchodilator used for emphysema, bronchitis and asthma.

    Categories: Adrenergics for Systemic Use
  8. Drug

    Sulfacetamide

    go.drugbank.com/drugs/DB00634
    Approved

    An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.

    Categories: Anti-Acne Preparations for Topical Use
  9. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes.

  10. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.